Onychomycosis Treatment Market Size

Onychomycosis Treatment Market Insights

Onychomycosis Treatment Market size was valued at USD 4.91 Billion in 2023 and is poised to grow from USD 5.33 Billion in 2024 to USD 10.32 Billion by 2032, growing at a CAGR of 8.60% during the forecast period (2025-2032).

The onychomycosis treatment market emphasizes treatments for nail fungal infections. The market comprises topical treatments, laser therapies, and oral antifungal medications. The growing cases of onychomycosis, several improvements in the treatment alternatives, and the rising awareness of the condition are majorly propelling the growth of the onychomycosis treatment market. Another key factor driving the growth of the market comprises increasing healthcare spending that allows better access to improved treatments. Nonetheless, a few restraining factors impeding the market growth include significantly priced treatment and side effects of the treatment. Most treatments, mainly advanced laser treatments and oral antifungal therapies are costly, which could lower its preference. Also, medications like itraconazole and terbinafine may cause harm to the liver and gastrointestinal issues, leading to patient hesitancy. Yet, a few opportunities witnessed in the market are innovations in drug development and improvements in drug delivery systems like nanotechnology-based products, sustained-release formulations, and highly effective topical treatments.

FAQs

The global Onychomycosis Treatment market is a highly competitive global market driven by a large number of international competitors. Prominent corporations with cutting-edge AI and ML technology are Google, IBM, Microsoft, and NVIDIA. To support a wide range of applications across industries, these industry experts concentrate on creating cutting-edge algorithms, scalable platforms, and reliable infrastructure. Rapid advances in technology, strategic alliances, and large expenditures on research and development define the competitive environment. 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Sanofi S.A. (France) ', 'Medimetriks Pharmaceuticals, Inc. (US) ', 'Galderma (Switzerland) ', 'Johnson & Johnson (US) ', 'Novartis AG (Switzerland) ', 'Moberg Pharma AB (Sweden) ', 'Cardinal Health, Inc. (US) ', 'Pfizer Inc. (US) ', 'Almirall, S.A. (Spain) ', 'Bayer AG (Germany) ', 'Viatris Inc. (US) ', 'GlaxoSmithKline plc (UK) ', 'Cipla Ltd. (India) ', 'Dr. Reddy’s Laboratories Ltd. (India) ', 'Evofem Biosciences, Inc. (US) ', 'Nabriva Therapeutics plc (Ireland) ', 'Kaken Pharmaceutical Co., Ltd. (Japan) ', 'Hikma Pharmaceuticals PLC (UK) ', 'Dermavant Sciences, Inc. (US) ', 'Sientra, Inc. (US) ', 'Zynerba Pharmaceuticals, Inc. (US)'

The growing cases of fungal nail infection because of the aging population, growing diabetes cases, and growing rate of conditions that lower the immune system is fueling the growth of the onychomycosis treatment market. Moreover, the growing awareness of the condition among patients and regarding the diagnosis and advanced treatments among healthcare professionals is resulting in an increasing number of diagnoses.

Blue Light and Carbon Dioxide Lasers: Carbon Dioxide lasers and Blue Light are adopted to cure toenail fungus, with CO2 lasers leading in adoption. These lasers can penetrate deep areas in the nail and reach the infection effectively. The blue light lasers are used for mild cases or in conjunction with different treatments, both approaches work by offering heat energy to demolish the fungus.

Geographically, North America is the dominating region among others and is expected to lead over the forecast period owing to the growing cases of onychomycosis due to many factors like growing prevalence of diabetes, ageing population, and lifestyle changes, especially in the leading nations like Canada and the United States. The growing awareness among the patients and the medical professionals regarding fungal infections of nail is notably contributing to the increased diagnosis and the number of treatment rates. The region is also benefitted by the high-tech healthcare infrastructure, comprising easy access to many treatment options and advanced diagnostic technologies. The key players operating in the region include Bausch Health Companies Inc., Pfizer Inc., Johnson & Johnson Services, Inc. and more.